HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Sancho, M. Articles by Leite, V. Search for Related Content PubMed PubMed Citation Articles by Sancho, M. Articles by Leite, V.

¹ Molecular Endocrinology, Centro de Investigação de Patobiologica Molecular (CIPM), Instituto Português de Oncologia Francisco Gentil, Rua Professor Lima Basto, 1099-023 Lisboa, Portugal
² Angiogenesis Group, Centro de Investigação de Patobiologica Molecular (CIPM), Instituto Português de Oncologia Francisco Gentil, Rua Professor Lima Basto, 1099-023 Lisboa, Portugal
³ Department of Pathology, Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal
⁴ Instituto de Medicina Molecular and
⁵ Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisboa, Portugal

(Requests for offprints should be addressed to V Leite; Email: vleite{at}ipolisboa.min-saude.pt)

The chemokine receptor CCR7 plays a critical role in lymphocyte and dendritic cell trafficking into and within lymph nodes, the preferential metastatic site for papillary (PTC) and medullary (MTC) thyroid carcinomas. In order to determine a possible role for CCR7 in mediating the metastatic behaviour of thyroid carcinomas, we analysed its expression in normal and tumoral thyroid tissues of different histotypes and studied the in vitro effects of its activation by the CCR7 ligand, CCL21. Using real-time quantitative-PCR, we observed that CCR7 expression was higher in PTCs and MTCs than in follicular and poorly differentiated thyroid carcinomas. CCR7 expression was ninefold higher in classic compared with follicular variants of PTCs, and its expression in MTCs was significantly correlated with lymph node metastases. Immunohistochemical staining for CCR7 showed protein expression in neoplastic thyroid cells, with higher intensity in PTCs, MTCs and their lymph node metastases (LNMs). We further showed that CCL21 stimulation of a CCR7-expressing thyroid tumour cell line (TPC-1) promotes cell proliferation and migration, and the chemotactic effect of CCL21 in these cells involves actin polymerization, increased ß1-integrin expression and increased matrix metalloproteinase secretion. Taken together, our results demonstrate that CCR7 activation on thyroid carcinoma cells by CCL21 – a chemokine abundantly expressed in lymph nodes – favours tissue invasion and cell proliferation, and therefore may promote thyroid carcinoma growth and LNM.

This article has been cited by other articles:

				P. L. Wagner, T.-A. Moo, N. Arora, Y.-F. Liu, R. Zarnegar, T. Scognamiglio, and T. J. Fahey III The Chemokine Receptors CXCR4 and CCR7 are Associated with Tumor Size and Pathologic Indicators of Tumor Aggressiveness in Papillary Thyroid Carcinoma Ann. Surg. Oncol., October 1, 2008; 15(10): 2833 - 2841. [Abstract] [Full Text] [PDF]

				E. Ziegler, M. Oberbarnscheidt, S. Bulfone-Paus, R. Forster, U. Kunzendorf, and S. Krautwald CCR7 Signaling Inhibits T Cell Proliferation J. Immunol., November 15, 2007; 179(10): 6485 - 6493. [Abstract] [Full Text] [PDF]